Zhaohui Ni, Zhen Zhang, Zanzhe Yu, Fuming Lu, Changlin Mei, Xiaoqiang Ding, Weijie Yuan, Wei Zhang, Gengru Jiang, Min Sun, Liqun He, Yueyi Deng, Huihua Pang, Jiaqi Qian
BACKGROUND: Immunoglobulin A nephropathy (IgAN) is the most common cause of glomerulonephritis worldwide, and the optimal approach to its treatment remains a significant challenge. METHODS: We did a prospective, randomized, open-labeled, multicenter, controlled trial, comprised of 3-month run-in, 12-month treatment, and 12-month follow-up phases. After 3-month run-in phase, patients with biopsy-confirmed IgAN at risk of progression were randomly allocated to LEF plus low-dose prednisone (LEF + prednisone group) or conventionally accepted-dose prednisone [prednisone(alone) group] Our primary outcome was 24-h urine protein excretion (UPE) and secondary outcomes were serum albumin (sALB), serum creatinine (Scr), and eGFR...
December 2021: Renal Failure